Literature DB >> 30340047

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

David A Quigley, Ha X Dang, Shuang G Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J Alumkal, Adam Foye, Vishal Kothari, Marc D Perry, Adina M Bailey, Denise Playdle, Travis J Barnard, Li Zhang, Jin Zhang, Jack F Youngren, Marcin P Cieslik, Abhijit Parolia, Tomasz M Beer, George Thomas, Kim N Chi, Martin Gleave, Nathan A Lack, Amina Zoubeidi, Robert E Reiter, Matthew B Rettig, Owen Witte, Charles J Ryan, Lawrence Fong, Won Kim, Terence Friedlander, Jonathan Chou, Haolong Li, Rajdeep Das, Hui Li, Ruhollah Moussavi-Baygi, Hani Goodarzi, Luke A Gilbert, Primo N Lara, Christopher P Evans, Theodore C Goldstein, Joshua M Stuart, Scott A Tomlins, Daniel E Spratt, R Keira Cheetham, Donavan T Cheng, Kyle Farh, Julian S Gehring, Jörg Hakenberg, Arnold Liao, Philip G Febbo, John Shon, Brad Sickler, Serafim Batzoglou, Karen E Knudsen, Housheng H He, Jiaoti Huang, Alexander W Wyatt, Scott M Dehm, Alan Ashworth, Arul M Chinnaiyan, Christopher A Maher, Eric J Small, Felix Y Feng.   

Abstract

Entities:  

Year:  2018        PMID： 30340047     DOI： 10.1016/j.cell.2018.10.019

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


× No keyword cloud information.
  39 in total

1.  Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.

Authors:  Melissa A Reimers; Steven M Yip; Li Zhang; Marcin Cieslik; Mallika Dhawan; Bruce Montgomery; Alexander W Wyatt; Kim N Chi; Eric J Small; Arul M Chinnaiyan; Ajjai S Alva; Felix Y Feng; Jonathan Chou
Journal:  Eur Urol       Date:  2019-10-20       Impact factor: 20.096

2.  The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.

Authors:  Wenjing Su; Hyun Ho Han; Yan Wang; Boyu Zhang; Bing Zhou; Yuanming Cheng; Alekya Rumandla; Sreeharsha Gurrapu; Goutam Chakraborty; Jie Su; Guangli Yang; Xin Liang; Guocan Wang; Neal Rosen; Howard I Scher; Ouathek Ouerfelli; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2019-07-18       Impact factor: 31.743

3.  ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.

Authors:  Shahrzad Rafiei; Kenyon Fitzpatrick; David Liu; Mu-Yan Cai; Haitham A Elmarakeby; Jihye Park; Cora Ricker; Bose S Kochupurakkal; Atish D Choudhury; William C Hahn; Steven P Balk; Justin H Hwang; Eliezer M Van Allen; Kent W Mouw
Journal:  Cancer Res       Date:  2020-03-03       Impact factor: 12.701

4.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Authors:  Michael D Nyquist; Alexandra Corella; Ilsa Coleman; Navonil De Sarkar; Arja Kaipainen; Gavin Ha; Roman Gulati; Lisa Ang; Payel Chatterjee; Jared Lucas; Colin Pritchard; Gail Risbridger; John Isaacs; Bruce Montgomery; Colm Morrissey; Eva Corey; Peter S Nelson
Journal:  Cell Rep       Date:  2020-05-26       Impact factor: 9.423

5.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Alessandro Romanel; Vincenza Conteduca; Nicola Casiraghi; Michael Sigouros; Gian Marco Franceschini; Francesco Orlando; Tarcisio Fedrizzi; Sheng-Yu Ku; Emma Dann; Alicia Alonso; Juan Miguel Mosquera; Andrea Sboner; Jenny Xiang; Olivier Elemento; David M Nanus; Scott T Tagawa; Matteo Benelli; Francesca Demichelis
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.

Authors:  Wassim Abida; Joshi J Alumkal; Rahul R Aggarwal; Michael T Schweizer; David M Nanus; Allan J Pantuck; Elisabeth I Heath; Eric Campeau; Sarah Attwell; Karen Norek; Margo Snyder; Lisa Bauman; Sanjay Lakhotia; Felix Y Feng; Eric J Small
Journal:  Clin Cancer Res       Date:  2020-07-21       Impact factor: 12.531

7.  Functional mapping of androgen receptor enhancer activity.

Authors:  Chia-Chi Flora Huang; Shreyas Lingadahalli; Tunc Morova; Dogancan Ozturan; Eugene Hu; Ivan Pak Lok Yu; Simon Linder; Marlous Hoogstraat; Suzan Stelloo; Funda Sar; Henk van der Poel; Umut Berkay Altintas; Mohammadali Saffarzadeh; Stephane Le Bihan; Brian McConeghy; Bengul Gokbayrak; Felix Y Feng; Martin E Gleave; Andries M Bergman; Colin Collins; Faraz Hach; Wilbert Zwart; Eldon Emberly; Nathan A Lack
Journal:  Genome Biol       Date:  2021-05-11       Impact factor: 13.583

Review 8.  Androgen Receptor Dependence.

Authors:  Aashi P Chaturvedi; Scott M Dehm
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Accelerating precision medicine in metastatic prostate cancer.

Authors:  Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R Soule; Arul Chinnaiyan; Eric Small; Jonathan W Simons; William Dahut; Andrea K Miyahira; Himisha Beltran
Journal:  Nat Cancer       Date:  2020-11-17

Review 10.  The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.

Authors:  Mingyue Xia; Zhigang Guo; Zhigang Hu
Journal:  Biomolecules       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.